Categories
Подкатегории
Maviret is indicated for the treatment of chronic hepatitis C infection (HCV) in adults and adolescents aged 12 to <18 years
Copegus is indicated in combination with peginterferon alfa-2a or interferon alfa-2a for the treatment of chronic hepatitis C in adult patients whose serum was determined by HCV RNA, including patients with cirrhosis in the compensation phase.
Copegus is indicated in combination with peginterferon alfa-2a or interferon alfa-2a for the treatment of chronic hepatitis C in adult patients whose serum was determined by HCV RNA, including patients with cirrhosis in the compensation phase.
Primary vaccination and revaccination of children against:
diphtheria
tetanus
whooping cough
hepatitis B
Polio
Haemophilus influenzae type b infection.
Primary vaccination and revaccination of children against:
diphtheria
tetanus
whooping cough
hepatitis B
Polio
Haemophilus influenzae type b infection.
Primary vaccination and revaccination of children against:
diphtheria
tetanus
whooping cough
hepatitis B
Polio
Haemophilus influenzae type b infection.
Treatment of chronic hepatitis C genotype 1 in adult patients with compensated liver disease (including cirrhosis) in combination with peginterferon alfa and ribavirin:
Léčivo je antivirové léčivo obsahující účinné látky elbasvir a grazoprevir.
Na co se používá?
Lék se používá k léčbě chronické hepatitidy C u dospělých ve věku 18 let a starších....
Медицина для улучшения субъективные трудности при заболеваниях печени, корректировка баланса крови жиры, стабилизации желчи.